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ABSTRACT 
G-Proteins  are  membrane-bound  beterotrimeric  polypeptides  that 
couple  receptor  signals  to  second  messenger  systems  such  as  CAMP. 
Recently,  point  mutations  at  2  codons  of  the  highly  preserved  a-chain 
of  G,,  the  adenyl  cyclase-stimulating  G-protein,  were  found  in  GH- 
secreting  pituitary  tumors.  These  mutations  resulted  in  constitutively 
activated  G,a  and  high  intracellular  CAMP  levels.  In  addition,  point 
mutations  at  similar  codons  of  a  different  G-protein,  G,o12,  were  re- 
ported  in  adrenocortical  neoplasms,  suggesting  a  potential  role  of  this 
isoform  in  the  genesis  of  these  tumors.  We  reevaluated  the  frequency 
of  constitutively  activating  point  mutations  in  the  a-chain  of  the 
stimulatory  (G,ol)  and  inhibitory  (Gicu2)  G-proteins  in  human  adreno- 
cortical  tumors.  Seven  adrenocortical  carcinomas,  2  human  adrenocor- 
tical  tumor  cell  lines,  and  11  adrenocortical  adenomas  were  studied. 
Genomic  DNA  was  purified  from  either  frozen  tumor  tissue  or  paraffin- 
embedded  sections.  Using  specific  primers  and  the  polymerase  chain 
reaction,  DNA  fragments  surrounding  codons  201  and  227  (G,oc)  and 
179  and  205  (G,a2)  were  amplified  and  visualized  on  a  2%  agarose  gel. 
In  a  second  asymmetric  polymerase  chain  reaction,  using  nested 
primers,  single  stranded  DNA  was  generated  using  l-10  FL  of  the 
initial  amplification  mixture  and  directly  sequenced  using  the  dideoxy 
chain  termination  method  of  Sanger.  We  found  no  mutations  at  codons 
201,  227  and  179,  205  of  G,a  and  G,a2,  respectively,  in  the  tumors 
studied.  We  conclude  that  previously  identified  oncogenic  point  muta- 
tions  in  the  stimulatory  and  inhibitory  a-chain  of  G-proteins  do  not 
appear  to  be  present  at  high  frequency  in  adrenal  neoplasms.  Thus,  the 
mechanism(s)  of  tumorigenesis  in  these  tumors  is  different  from  that 
in  GH-secreting  adenomas  and  may  involve  oncogenic  mutations  of 
other  cell  constituents.  (J  Clin  Endocrinol  Metab  ‘7’7:  1419-1422,1993) 
T 
WO  DECADES  ago, adrenocortical neoplasms  were con- 
sidered rare. However,  with  wider  application  of  ultra- 
sound, computed tomography,  and, more recently,  magnetic 
resonance  imaging, it became evident  that  the prevalence of 
clinically  silent,  incidentally  detected adrenal neoplasms  is 
much  higher  than  previously  assumed (1).  However,  the 
tumorigenesis  of adrenocortical neoplasms  is not well under- 
stood, and the  molecular mechanisms that  lead to  adrenal 
tumor  formation  have not been extensively  studied. 
G-Proteins involved  in  signal transduction  are heterotri- 
mers consisting of  cy-, P-, and y-subunits  that  bind guanine 
nucleotide and interact  with  specific receptors and effecters 
(2). G-Protein  activation  normally  requires the interaction  of 
the inactive GDP-bound  heterotrimer with  a ligand-occupied 
receptor,  resulting  in  the  exchange  of  GTP  for  GDP  and 
dissociation of  the a-unit  (3). Recently,  mutations in  the (Y- 
unit  of  G,,  the  adenylyl  cyclase-stimulating  protein,  have 
been  described in  GH-secreting  pituitary  adenomas (4). 
These  mutations caused  an amino acid exchange at the highly 
conserved codons Arg*”  and Gln227,  resulting in a constitu- 
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tive  activation  of  G,a  by  inhibition  of  endogenous GTPase 
activity.  These putative  oncogenic mutations,  which  were 
called  Gsp, were found  in  approximately  40%  of  GH-pro- 
ducing  tumors and 4% of  thyroid  tumors (5, 6). Point  mu- 
tations at similar codons of a different  G-protein,  codons 179 
and 205 of G,a2, were reported in adrenocortical neoplasms, 
suggesting a potential  role of  mutated  Gi(u2 (Gip  2)  in  the 
tumorigenesis of  adrenocortical  masses  (5).  However,  the 
initially  described series  was rather  small (n =  ll),  demon- 
strating  mutations  in  three  (27%)  tumors.  We,  therefore, 
reevaluated  the frequency  of  Gsp  and Gip  2 in a larger series 
of adrenocortical tumors. 
Subjects  and  Methods 
Isolation  of DNA  from  tissue  specimens 
Adrenocortical  tumor  tissue  was  obtained  at  adrenalectomy  from  18 
patients.  DNA  was  isolated  from  7  adrenocortical  carcinomas  and  11 
adrenocortical  adenomas  (for  clinical  data,  see  Table  1).  In  10  cases, 
tumor  DNA  was  extracted  from  paraffin-embedded  sections  accumu- 
lated  over  a  30.yr  period.  In  8  cases,  frozen  (-80  C)  tumor  tissue  and 
corresponding  normal  leukocytic  DNA  were  studied.  In  addition,  DNA 
from  the  2  currently  available  human  adrenocortical  tumor  cell  lines 
were  studied.  SW13,  a  nonsecretory  human  adrenocortical  tumor  cell 
line  maintained  in  Ham’s  F-10  medium  with  10%  fetal  bovine  serum, 
was  received  from  the  American  Type  Culture  Collection  (Rock- 
ville,  MD).  NC1  H-295,  a  human  steroid-producing  adrenocortical  tumor 
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ABSTRACT 
G-Proteins are  membrane-bound heterotrimeric polypeptides that 
couple  receptor signals to second messenger systems such as cAMP. 
Recently, point mutations at 2 codons of the highly preserved a-chain 
of G"  the adenyl  cyc1ase-stimulating G-protein,  were  found  in  GH-
secreting pituitary tumors. These mutations resulted in constitutively 
activated G,a and high intracellular cAMP levels.  In addition, point 
mutations at similar codons of a different G-protein,  Gia2,  were  re-
ported in adrenocortical neoplasms, suggesting a potential role of this 
isoform in the genesis of these tumors, We reevaluated the frequency 
of  constitutively  activating  point  mutations  in  the  a-chain  of the 
stimulatory (G,a) and inhibitory (Gio:2)  G-proteins in human adreno-
cortical tumors, Seven adrenocortical carcinomas, 2 human adrenocor-
tical tumor cell  lines,  and 11  adrenocortical adenomas were  studied. 
T
WO DECADES ago, adrenocortical neoplasms were con-
sidered rare,  However, with wider application of ultra-
sound, computed tomography, and, more recently, magnetic 
resonance imaging, it became evident that the prevalence of 
clinically silent,  incidentally detected adrenal neoplasms is 
much  high  er  than  previously  assumed  (1),  However,  the 
tumorigenesis of adrenocortical neoplasms is not wen under-
stood, and the molecular mechanisms that lead to  adrenal 
tumor formation have not been extensively studied. 
G-Proteins involved in  signal transduction are heterotri-
mers consisting of a-, ß-, and ')'-subunits that bind guanine 
nucleotide and interact with specific receptors and effectors 
(2), G-Protein activation normally requires the interaction of 
the inactive GDP-bound heterotrimer with a ligand-occupied 
receptor,  resulting  in  the  exchange  of  GTP  for  GDP  and 
dissociation of the a-unit (3),  Recently,  mutations in the a-
unit of  GS!  the  adenylyl  cyclase-stimulating pro  tein,  have 
been  described  in  GH-secreting  pituitary  adenomas  (4), 
These mutations caused an amino acid exchange at the highly 
conserved co dons Arg
201  and Gln
227
,  resulting in a constitu-
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Genomic DNA was purified from either frozen tumor tissue or paraffin-
embedded sections, Using specific primers and the polymerase chain 
reaction, DNA fragments surrounding codons 201  and 227  (G,a) and 
179 and 205 (Gio:2)  were amplified and visualized on a 2% agarose geL 
In  a  second  asymmetrie  polymerase  chain  reaetion,  using  nested 
primers,  single  stranded DNA was  generated using  1-10 ILL  of the 
initial amplifieation mixture and directly sequenced using the dideoxy 
chain termination method of Sanger, We found no mutations at codons 
201,  227  and 179,  205  of G,a and Gia2,  respectively,  in  the tumors 
studied, We conclude that previously identified oncogenie point muta-
tions in the stimulatory and inhibitory a-chain of G-proteins do  not 
appear to be present at high frequency in adrenal neoplasms, Thus, the 
mechanism(s) of tumorigenesis in these tumors is different from that 
in  GH-secreting adenomas and may  involve  oncogenic  mutations of 
other cell constituents. (J Clin Endocrinol Metab 77: 1419-1422, 1993) 
tive activation of Gsa by inhibition of endogenous GTPase 
activity,  These  putative  oncogenic  mutations,  which  were 
called Gsp,  were found in approximately 40%  of GH-pro-
ducing tumors and 4%  of thyroid tumors (5,  6),  Point mu-
tations at similar codons of a different G-protein, codons 179 
and 205 of G;a2, were reported in adrenocortical neoplasms, 
suggesting a  potential role of mutated G;a2  (Gip  2)  in  the 
tumorigenesis  of  adrenocortical  masses  (5),  However,  the 
initially described series was rather small (n  =  11),  demon-
strating  mutations  in  three  (27%)  tumors,  We,  therefore, 
reevaluated the frequency of Gsp and Gip 2 in a larger series 
of adrenocortical tumors, 
Subjects and Methods 
Isolation of DNA from tissue specimens 
Adrenocortical tumor tissue was obtained at adrenalectomy from  18 
patients,  DNA  was isolated from  7 adrenocortical  cardnomas and 11 
adrenocortical adenomas  (for  clinical  data,  see  Table  1),  In  10  cases, 
tumor DNA  was extracted from  paraffin-embedded seetions accumu-
la ted over a 30-yr pcriod. In  8 ca ses, frozen (-80 C) tumor tissue and 
corresponding normal leukocytic DNA were studied, In addition, DNA 
from  the  2 currently available human adrenocortical tumor cell  lines 
were studied,  SW13,  a nonsecretory human adrenocortical tumor cell 
line maintained in Ham's F-10 medium with 10%  fetal  bovine serum, 
was  received  from  the  American  Type  Culture  Collection  (Rock-
ville, MD), NCl H-295, a human steroid-producing adrenocortical tumor 1420  COMMENTS  JCE  &  M  .1993 
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TABLE  1.  Clinical  data  of  the  patients  whose  tumors  were  studied 
Patient  SC3  Age  Tumor  size 
no.  (Yd  (cm) 
Histology  Clinical  presentation 
1  F  15  25  x  17  x  8  Liver  met.,  adren.  cam.  Virilization 
2  F  50  9x8x7  Adren.  cart.  Conn’s  syndrome 
3  M  25  9x8x5  Adren.  cart.  Cushing’s  syndrome,  MEN  I 
4  F  14  7~4x2  Liver  met.,  adren.  cart.  Non-secretory  tumor 
5  F  29  8X6X1  Brain  met,  adren.  cart.  Non-secretory  tumor 
6  F  22  12  x  6  x  10  Adren.  cart.  Cushing’s  syndrome 
7  F  27  17  cm  diam.  Adren.  cart.  Virilization 
8  F  67  2.5  cm  diam.  Adrenal  adenoma  Cushing’s  syndrome 
9  F  65  4X5X3  Adrenal  adenoma  Cushing’s  syndrome 
10  F  41  3  cm  diam.  Adrenal  adenoma  Conn’s  syndrome 
11  F  49  3  cm  diam.  Adrenal  adenoma  Cushing’s  syndrome 
12  F  50  1  cm  diam.  Adrenal  adenoma  Conn’s  syndrome 
13  F  39  4X4X3  Adrenal  adenoma  Cushing’s  syndrome 
14  F  51  1.5  cm  diam.  Adrenal  adenoma  Conn’s  syndrome 
15  F  39  2X2X1  Adrenal  adenoma  Conn’s  syndrome 
16  F  48  3x3x2  Adrenal  adenoma  Conn’s  syndrome 
17  F  30  4x2x2  Adrenal  adenoma  Conn’s  syndrome 
18  F  48  1x3  Adrenal  adenoma  Conn’s  syndrome 
Adr.  cant.,  Adrenocortical  carcinoma;  met.,  metastsis;  diam.,  diameter;  MEN  I,  multiple  endocrine  neoplasia  type  1. 
DNA  source 
Frozen  tissue 
Frozen  tissue 
Paraffin 
Paraffin 
Paraffin 
Paraffin 
Paraffin 
Frozen  tissue 
Frozen  tissue 
Frozen  tissue 
Frozen  tissue 
Frozen  tissue 
Frozen  tissue 
Paraffin 
Paraffin 
Paraffin 
Paraffin 
Paraffin 
cell  line  maintained  in  HITES  (containing  hydrocortisone,  insulin,  eth- 
anolamine  and  selenite)  medium  with  2%  fetal  bovine,  was  kindly 
provided  by  Dr.  E.  Gazdar  (7). 
DNA  preparation 
DNA  was  isolated  from  paraffin-embedded  specimens  (8),  leukocytes, 
or  frozen  tumor  sections  obtained  at  surgery  (9),  as  previously  described. 
Tissue  samples  were  derived  from  a  central  portion  of  the  tumor  to 
minimize  the  possibility  of  contamination  with  normal  tissue.  Repre- 
sentative  sections  of  the  tumor  material  were  examined  by  light  micros- 
copy  and  shown  to  consist  of  more  than  90%  tumor  cells.  For  paraffin- 
embedded  specimens,  IO-pm  sections  were  carefully  cut  and  placed  in 
sterile  Eppendorf  tubes  using  new  gloves,  forceps,  and  a  cleaned  micro- 
tome  blade  for  every  tumor  block. 
Polymerase  chain  reaction  (PCR)  amplification  of genomic 
DNA 
PCR  was  used  to  amplify  DNA  fragments  surrounding  codons  201 
and  227  of  G$a  and  codons  179  and  205  of  G,a2,  respectively  (10).  One 
and  10  FL  DNA  preparation  from  paraffin-embedded  tissues  or  1  pg 
DNA  from  frozen  tissue  or  leukocytic  DNA  were  amplified  in  a  IOO-rL 
PCR  mixture  containing  deoxynucleotide  triphosphates  (200  wmol/L 
each),  up-  and  down-stream  oligonucleotide  primers  (0.3  pmol/L  each), 
0.01%  gelatin,  50  mmol/L  KCI,  10  mmol/L  Tris-HCl  (pH  8.3),  1.5  mmol/ 
L  MgC12,  and  2.5  U  Ta9  polymerase  (Perkin-Elmer  Cetus,  Norwalk,  CT). 
The  following  primers  were  used:  codon  201  of  G,a,  5’-GTG  ATC  AAG 
CAG  GCT  GAC  TAT  GTG-3’  and  5’-GGT  GAA  TGT  CAA  GAA  ACC 
ATG-3’  [299-basepair  (bp)  fragment];  codon  227  of  G,oc,  5’.GTC  AAC 
TTC  CAG  TAA  GCC  AAC-3’  and  5’-CTG  GTT  GTC  CTC  CCG  GAT 
GAC-3’  (350  bp);  codon  179  of  Gicu2,  5’CCC  CCC  ATC  CCC  AGC 
TAC  CT-3’  and  5’-CCG  ACC  TGT  CCA  CAT  GCT  CGC-3’  (168  bp); 
and  codon  205  of  Gicu2,  5’-GAG  AAA  TGG  GGT  AGA  AAG  CCT-3’ 
and  5’.TCT  CAC  CAT  CTC  CTC  GTC  CTC-3’  (195  bp).  Special 
precautions  were  taken  to  avoid  contamination  of  the  I’CR  samples.  In 
all  PCR  experiments,  samples  containing  no  DNA  were  included  as 
negative  controls.  The  amplification  protocol  consisted  of  denaturation 
at  95  C  for  5  min,  followed  by  30-40  cycles  consisting  of  annealing  at 
55  C  for  1.5  min,  primer  extension  at  72  C  for  1.5  min,  and  denaturation 
at  94  C  for  1  min.  All  amplified  samples  were  examined  by  agarose  gel 
electrophoresis  to  confirm  successful  amplification  of  each  of  the  regions 
of  the  Gsa  and  G,a2  genes. 
Direct  sequencing  of the  PCR  product 
In  a  second,  asymmetric  PCR,  using  one  of  the  nested  primers  in  a 
loo-fold  excess,  single  stranded  DNA  was  generated,  purified  on  Ultra- 
pure  MC  filters  (Millipore,  Bedford,  MA),  and  lyophilized  at  room  tem- 
perature.  Using  the  dideoxy  chain  termination  method  of  Sanger  et  al. 
(1  I),  the  PCR  product  was  sequenced  (T7-DNA  polymerase,  Sequenase 
2.0,  U.S.  Biochemical  Corp.,  Cleveland,  OH)  with  [a-35S]deoxy-ATP  and 
run  on  a  6%  denaturing  polyacrylamide  gel.  Autoradiography  was 
performed  with  Kodak  XAR  2  films  (Eastman  Kodak,  Rochester,  NY). 
Results 
In  all but  two  cases,  DNA  fragments surrounding  codons 
201 and 227 of  G,LY and codons 179 and 205 of  Gia2 were 
successfully amplified  by  PCR  and  showed  the  predicted 
size on agarose  gel electrophoresis. In two  31- and 32-yr-old 
paraffin-embedded  tumor  specimens, the  299- and 350-bp 
long fragments surrounding  codons 201 and 227 could not 
be amplified,  probably  due to  DNA  degradation,  whereas 
the shorter fragments surrounding  codons 179 (168 bp) and 
205 (195 bp) could be efficiently  amplified  in these cases. 
Direct  sequencing of  the  PCR product  from  normal leu- 
kocyte  DNA  revealed the wild-type  sequence  for  the ampli- 
fied  regions. All  adrenal adenomas, all adrenocortical carci- 
nomas, and the two  adrenocortical tumor  cell lines showed 
only  the wild-type  sequence at codons 201 and 227 of  G,a 
and  codons 179 and  205 of  Gia2  (Table  2 and Fig.  1). In 
addition,  no mutations were found  at other  codons of  G,a 
and G,o12  in  these amplifications. 
Discussion 
Constitutively  activating  mutations  in  G-proteins  were 
found  in several endocrine neoplasms.  Adenylcyclase activity 
was extremely  elevated  under basal conditions in  these tu- 
mors  (12).  Clinically,  the  GH-secreting  adenomas were 
smaller in  diameter,  less responsive to  GH-releasing-hor- 
mone, and  more sensitive to  somatostatin- and  dopamine- 
induced  GH  inhibition  than  adenomas  with  no mutated  G, 
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TABLE  1. Clinieal data of the patients whose tumors were studied 
Patient  Sex  Age  Tumor size  Histology  Clinieal presentation  DNA souree  no.  (yr)  (ern) 
1  F  15  25  X 17  X 8  Liver met., adren. eare.  Virilization  Frozen tissue 
2  F  50  9x8x7  Adren. care.  Conn's syndrome  Frozen tissue 
3  M  25  9x8x5  Adren. care.  Cushing's syndrome, MEN I  Paraffin 
4  F  14  7x4x2  Liver met., adren. carc.  Non-secretory tumor  Paraffin 
5  F  29  8x6x1  Brain met, adren. eare.  Non-seeretory tumor  Paraffin 
6  F  22  12  x  6 X 10  Adren. carc.  Cushing's syndrome  Paraffin 
7  F  27  17 cm diam.  Adren. care.  Virilization  Paraffin 
8  F  67  2.5 cm diam.  Adrenal adenoma  Cushing's syndrome  Frozen tissue 
9  F  65  4x5x3  Adrenal adenoma  Cushing's syndrome  Frozen tissue 
10  F  41  3 em diam.  Adrenal adenoma  Conn's syndrome  Frozen tissue 
11  F  49  3 cm diam.  Adrenal adenoma  Cushing's syndrome  Frozen tissue 
12  F  50  1 cm diam.  Adrenal adenoma  Conn's syndrome  Frozen tissue 
13  F  39  4x4x3  Adrenal adenoma  Cushing's syndrome  Frozen tissue 
14  F  51  1.5 em diam.  Adrenal adenoma  Conn's syndrome  Paraffin 
1."i  F  39  2x2x1  Adrenal adenoma  Conn's syndrome  Paraffin 
16  F  48  3x3x2  Adrenal adenoma  Conn's syndrome  Paraffin 
17  F  30  4x2x2  Adrenal adenoma  Conn's syndrome  Paraffin 
18  F  48  1 X  3  Adrenal adenoma  Conn's syndrome  Paraffin 
Adr. eane., Adrenoeortical carcinoma; met., metastsis; diam., diameter; MEN I, multiple endoerine neoplasia type 1. 
celliine maintained in  HITES  (containing hydrocortisone, insulin, eth-
anolamine  and  selenite)  medium  with  2%  fetal  bovine,  was  kindly 
provided by Dr.  E. Gazdar (7). 
DNA preparation 
DNA was iso la ted from paraffin-embedded specimens (8), leukocytes, 
or frozen tumor seetions obtained at surgery (9), as previously described. 
Tissue  sampies were  derived from  a  central  portion  of  the  tumor to 
minimize  the  possibility of contamination with normal  tissue.  Repre-
sentative seetions of the tumor material were examined by light micros-
eopy and shown to eonsist of more than 90% tumor cells. For paraffin-
embedded specimens, 10-ILm sections were carefully cut and placed in 
sterile Eppendorf tubes using new gloves, forceps, and a cleaned micro-
tome blade for every tumor block. 
Polymerase chain reaction (PCR) amplification of genomic 
DNA 
PCR  was used to  amplify DNA fragments surrounding codons 201 
and 227 of Gsa and codons 179 and 205 of G,a2, respectively (10). One 
and 10  IlL  DNA  preparation from  paraffin-embedded tissues or  1 ILg 
DNA from frozen bssue or leukocytic DNA were amplified in a 100-ILL 
PCR  mixture  containing  deoxynucleotide  triphosphates  (200  Ilmol/L 
each), up- and down-stream oligonucleotide primers (0.3 Ilmol/L each), 
0.01 % gelatin, 50 mmol/L KCI,  10 mmol/L Tris-HCI (pH 8.3),1.5 mmol/ 
L MgCIz, and 2.5 U Taq polymerase (perkin-Elmer Cetus, Norwalk, CT). 
The following primers were used: codon 201  of G,a, 5'  -GTG ATC AAG 
CAG GCT GAC TAT GTG-3' and 5'  -GGT GAA TGT CAA GAA ACC 
ATG-3' [299-basepair (bp) fragment]; codon 227 of Gsa, 5'  -GTC AAC 
TTC  CAG TAA  GCC AAC-3' and 5'-CTG GTT  GTC CTC  CCG GAT 
GAC-3' (350  bp);  codon  179  of  G;a2,  5'-CCC CCC  ATC  CCC  AGC 
TAC CT-3' and 5'-CCG ACC  TGT CCA CAT GCT CGC-3' (168 bp); 
and codon 205  of G;a2,  5'-GAG AAA  TGG GGT AGA  AAG  CCT-3' 
and  5'-TCT  CAC  CAT  CTC  CTC  GTC  CTC-3'  (195  bp).  Special 
precautions were taken to avoid contamination of the PCR sampies. In 
all  PCR  experiments,  sampies  containing  no  DNA  were  included as 
negative controls. The amplification protocol consisted of denaturation 
at 95  C for 5 min, followed by 30-40 cycles consisting of annealing at 
55 C for 1.5 min, primer extension at 72 C for 1.5 min, and denaturation 
at 94 C for 1 min. All amplified sam  pies were examined by agarose gel 
electrophoresis to confirm successful amplification of each of the regions 
of the G,a and Gia2 genes. 
Direct sequencing of the PCR product 
In a second, asymmetrie PCR,  using one of the nested primers in a 
100-fold excess, single stranded DNA was generated, purified on Ultra-
pure MC filters (Millipore, Bedford, MA),  and lyophilized at room tem-
perature. Using the dideoxy chain termination method of Sanger et  al. 
(11), the PCR product was sequenced (T7-DNA polymerase, Sequenase 
2.0, U.S. Biochemical Corp., Cleveland, OH) with [a-
35S]deoxy-ATP and 
run  on  a  6%  denaturing  polyacrylamide  gel.  Autoradiography  was 
performed with Kodak XAR 2 films (Eastman Kodak, Roehester, NY). 
Results 
In all but two cases, DNA fragments surrounding codons 
201  and 227 of Gsa and codons 179 and 205  of Gja2 were 
successfully  amplified  by PCR  and showed the  predicted 
size on agarose gel electrophoresis. In two 31- and 32-yr-old 
paraffin-embedded tumor specimens, the 299- and 350-bp 
long fragments surrounding co dons 201  and 227 could not 
be amplified,  probably due  to  DNA  degradation, whereas 
the shorter fragments surrounding codons 179 (168 bp) and 
205 (195 bp) could be efficiently amplified in these cases. 
Direct sequencing of the PCR  product from  normal leu-
kocyte DNA revealed the wild-type sequence for the ampli-
fied regions. All adrenal adenomas, all adrenocortical carci-
nomas, and the two adrenocortical tumor cell lines showed 
only the wild-type sequence at codons 201  and 227 of Gsa 
and codons  179  and 205  of Ga2 (Table  2 and Fig.  1).  In 
addition, no mutations were found at other co dons of Gsa 
and Gja2 in these amplifications. 
Discussion 
Constitutively  activating  mutations  in  G-proteins  were 
found in several endocrine neoplasms. Adenylcyclase activity 
was extremely elevated under basal conditions in these tu-
mors  (12).  Clinically,  the  GH-secreting  adenomas  were 
smaller  in  diameter,  less  responsive  to  GH-releasing-hor-
mone, and more sensitive to  somatostatin- and dopamine-
induced GH inhibition than adenomas with no mutated Gs COMMENTS  1421 
TABLE  2.  Prevalence  of oncogenic  point  mutations  in  the  a-chain 
of G,  and  GtP in  adrenocortical  tumors:  comparison  with  the  results  of 
Lyons  et al.  (5) 
G.a codon 
n  ZOl/codon 
Gicu2  codon  179fcodon 
221(%)  205  (%) 
Adrenal  carcinomas 
Reincke  et al.  7  0  0  0 
Lyons  et  al.  6  0  16.6  0 
Adrenocortical  tumor  cell  lines 
Reincke  et al.  2  0  0  0 
Adrenal  adenomas 
Reincke  et  al.  11  0  0  0 
Lyons  et  al.  5  0  40  0 
Gab  Codon  179 
NORMAL 
~\LYMPHOCYTES  CARCINOMA  1x1 
GATC  GATC 
Gaiz  Codon  205 
C 
Arg  206  G  11  G 
FIG.  1.  Sequencing  analysis  of  the  amplified  genomic  fragments  of 
Gia2  surrounding  codons  179  and  205  showing  only  the  wild-type 
sequence  in  normal  lymphocytic  DNA  (left)  and  DNA  from  an  adre- 
nocortical  carcinoma  (right). Top,  Codon  179; bottom,  codon  205. 
(12-14). Somatic mutations in G,cu  were also found  in benign 
and malignant thyroid  neoplasms.  Lyons et al. (5) reported  a 
low  incidence of  Gsp mutations in  thyroid  neoplasms  (1 of 
25  cases), whereas Suarez  et  al.  (6)  found  constitutively 
activating  mutations of  G,a  in  10% of  thyroid  tumors. Gor- 
etzki et al. (15) reported Gsp mutations in all 25 multinodular 
goiters studied from an iodine-deficient  area, but in none of 
3 thyroid  adenomas. The  Gsp mutations were  multifocally 
distributed  throughout  the tissue. These researchers, there- 
fore, concluded that  the Gsp  oncogene constituted one of the 
genetic bases  of  this disease.  Whereas Gsp is important  in 
endocrine tumors, it  does  not play  a role in the pathogenesis 
of  other  neoplasms. No  Gsp mutations  were found  in  218 
nonendocrine tumors studied, including  breast, colon,  and 
gastric carcinomas  (5). 
Somatic mutations in  a different  G-protein,  G,cu2,  corre- 
sponding to codons 201 and 227 of  Gs~, were identified  by 
Lyons et al. (5) in  3 of  11 (27%) adrenocortical neoplasms 
using  PCR  and  oligonucleotide-specific  hybridization.  Al- 
though  the  functional  significance of  these putative  onco- 
genie mutations Gip 2 was not proven,  several indirect  lines 
of  evidence  suggested,  promotion  of  cell  proliferation  by 
constitutively  activated  Gia2. However,  using PCR and direct 
sequencing, we were unable to confirm  the results of  Lyons 
et al. None of 7 adrenal carcinomas  and 11 adenomas  showed 
mutations  at  codons  179  and  205  of  Gia2.  In  addition, 
although  oncogenic mutations are generally  more frequent 
in human tumor cell lines  than in tumor tissue,  the 2 currently 
available  human  adrenocortical  tumor  cell lines had  wild- 
type  sequences  at codons 179 and 205 of  Gia2. The differ- 
ences  between our results  and the data of Lyons et al. cannot 
be explained  by  the  different  methodologies used in  these 
studies. Direct  sequencing  of PCR-amplified DNA  fragments 
is equally  sensitive in detecting point mutations in the tumor 
genome compared to allele-specific oligonucleotide  hybridi- 
zation,  which  was used by  Lyons et al. More likely,  our data 
suggest that  the  putative  oncogene Gip  2 does not  play  a 
major  role  in  the  tumorigenesis of  human  adrenocortical 
neoplasias. 
Several recent publications suggested  that oncogenes  other 
than  Gip 2 are involved  in  adrenocortical tumor  formation. 
Yano  ef al.  (16) consistently  showed loss of  constitutional 
heterozygosity  for  alleles  at chromosomes  llq,  13q, and 17p 
in  adrenocortical carcinomas, but  not  in  adrenal adenomas 
or hyperplastic  adrenal lesions. Chromosome llq  seems  to 
be important  in adrenal tumorigenesis. 1  lq13  is the locus of 
the  multiple  endocrine  neoplasia-1 tumor  suppressor gene 
(17),  and  adrenal tumor  formation  is part  of  this entity. 
However,  the  deletion  of  the  chromosomal region  llq13 
present in  parathyroid  and  pancreatic  tumors  (17)  is not 
always present in adrenal tumors of these patients (18). The 
Wiedemann-Beckwith  syndrome,  which  is associated with 
allelic loss of  1  lq15,  is characterized  by  early  development 
of Wilm’s tumors and adrenocortical carcinomas  (19). Chro- 
mosome 13 is the  locus of  the  retinoblastoma  gene (20); 
however,  no  studies have  been  reported  elucidating  the 
pathophysiological  significance of  retinoblastoma gene mu- 
tations in adrenal neoplasms. The short arm of chromosome 
17 contains the p53 gene, which  is most frequently  known 
to be mutated  in  human cancer (21). A  germ-line mutation 
in the p53 gene is associated  with  the Li-Fraumeni syndrome 
in  cancer-prone families (22) whose members  may  develop 
adrenocortical  carcinoma (23).  In  summary,  these data  to- 
gether  with  our  results show  that  molecular  mechanisms 
different  from the  previously  suggested  oncogenes  Gsp and 
Gip  2 are involved  in  the  tumorigenesis of  adrenocortical 
neoplasms. 
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T ABLE  2.  Prevalenee of oncogenie point mutations in the ",·ehain 
of G. and G,. in ad«!nocortieal tumors: comparison with the results of 
Lyons et al.  (5) 
G  •  ., codon  G;.,2 codan  179/cOOon  ,  201/cOOon 
227 (%)  205  (%) 
Adrenal carcinomas 
Reincke et al.  7  0  0  0 
Lyons et al.  6  0  16.6  0 
Adrenocortieal tumor cell lines 
Reincke et 01.  2  0  0  0 
Adrenal adenomas 
Reincke et al.  Il  0  0  0 
Lyons et 01.  5  0  40  0 
Gaj2 Codon 179 
NORMAL 
Val  180  [t
YMPHOCYTES  CARCI NOMA 
T  GATC  GATC 
G 
Val  180 
Arg  179 
Thr  178 
Gly  204 
Arg  206 
'"  ~ 
U 
Thr  178 
Gah Codon 205 
NORMAL 
LYMPHOCYTES 
G A T  C 
CARC INOMA j :l 
G  A  T  C  ~ 
~ 
\~ 
Gly  204 
Gin  205 
Arg  206 
FIG.  1.  Sequencing analysis of the  amplified  genomic  fragments  af 
0,,,,2 surrounding codons  179 and  205  shawing only  the  wild-type 
sequence in normal  lymphocytic DNA (kft) and DNA from an adre-
nocortical carcinoma (right). Top, Codon 179; bottom, codon 205. 
(12-14). Somatic mutations in G,a were also found in benign 
and malignant thyroid neoplasms. Lyons el  aI.  (5) reported a 
low incidence of Gsp  mutations in  thyroid neoplasms (1  of 
25  cases),  whereas  Suarez  cl  aI.  (6)  found  constitutively 
activating mutations of G.", in  10%  of thyroid tumors. Gor-
etzki el al. (15) reported Gsp mutations in all 25 multinodular 
goiters studied from an iodine-deficienl area, but in none of 
3 thyroid  adenomas.  The  Gsp  mutations were  multifocally 
distributed throughout the tissue. These researchers,  there-
fore, concluded that the Gsp oncogene constituted one of Ihe 
genetic bases of this disease.  Whereas Gsp  is  imporlant in 
endocrine tumors,  it does not playa role in the pathogenesis 
of other  neoplasms. No Gsp  mutations were found in  21 8 
nonenclocrine tumors studied, including breast, colon, and 
gastric carcinomas (5). 
Somatie mutations  in  a  different G-protein, G,a2,  corre-
sponding to codons 201 and 227 of G.a, were idenlified by 
Lyons el  aI.  (5)  in  3 of 11  (27%)  adrenocortical neoplasms 
using  PCR  and oligonucleotide-specific  hybridization.  AI-
though the functional  significance of these putative onco-
genie mutations Gip 2 was not proven, several indirect lines 
of  evidence  suggested  promotion  of  cell  proliferation  by 
constitutively activated G;a2. However, using PCR and direct 
sequencing,  we were unable to confirm the results of Lyons 
cf al. None of 7 adrenal carcinomas and 11 adenomas showed 
mutations  al  codons  179  and  205  of  G;a2.  In  addition, 
although oncogenic mutations are generally more frequent 
in human tumor celliines than in tumor tissue, the 2 currently 
available human adrenocortieal  tumor cell  lines  had  wild-
type sequences at codons 179  and 205 of G,a2. The diHer-
ences between our results and the data of Lyons Cl  aI. cannot 
be explained by  the different methodologies used in  these 
studies. Direct sequencing of PCR-amplified DNA fragments 
is equally sensitive in detecting point mutations in the tumor 
genome compared to allele-specific oligonucleolide hybridi-
zation, whieh was used by Lyons ct al.  More likely, our data 
suggest  thai  the putative oncogene Gip  2 cloes  not playa 
ma jor  role  in  the  tumorigenesis  of  human adrenocortical 
neoplasias. 
Several recent publications suggested that oncogenes other 
than Gip  2 are involved in adrenocortical  tumor  formation. 
Yano el  al.  (16) consistently  showed lass of constitutional 
heterozygosity for alleles at chromosomes 11q, 13q, and 17p 
in adrenocortical carcinomas, but not in adrenal adenomas 
or hyperplastic adrenal lesions.  Chromosome 11q seems to 
be important in adrenal tumorigenesis. 11q13 is the locus of 
the multiple endocrine neoplasia-l  tumor suppressor gene 
(17),  and  adrenal  tumor  formation  is  part  of  this  entity. 
However,  the  deletion  of the chromosomal  region  11q13 
present in  parathyroid  and  pancreatic  tumors  (17)  is  not 
always present in adrenal tumors of these patients (18). The 
Wiedemann-Beckwith  syndrome,  which  is  associated  with 
allelic loss of l1q15, is characterized by early development 
of Wilm's tumors and adrenocortieal cardnomas (19). Chro-
mosome  13  is  the  locus  of  the  retinoblastoma  gene  (20); 
however,  no  studies  have  been  reported  elucidating  the 
pathophysiological significance of retinoblastoma gene mu-
tations in adrenal neoplasms. The shorl arm of chromosome 
17  contains the pS3 gene, which is most frequently known 
to be mutated in human cancer (21).  A germ-line mutation 
in the p53 gene is associated with the Li-Fraumeni syndrome 
in cancer-prone families (22) whose members may develop 
adrenocortical  carcinoma  (23).  In  summary,  these data  to-
gether with  our  results  show  that  molecular  mechanisms 
different from the previously suggested oncogenes Gsp  and 
Gip  2 are  involved  in  the  tumorigenesis  of  adrenocortical 
neoplasms. 
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